- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Drug development for Alzheimer’s disease has been a series of disappointments, with only faint glimmers of hope from pharmaceutical companies or academic labs. What causes the disease is
still hotly debated, with the amyloid hypothesis losing believers after each new trial failure. But before those drugs targeting amyloid plaques or tau tangles failed in human trials, they
generally succeeded in preclinical studies — specifically, ones done with mice. Right now, about 160 mouse models for Alzheimer’s exist. But none is particularly good, experts say. This fall
Jackson Laboratory and Indiana University plan to release a handful of new Alzheimer’s mouse models into the world — the first of more than 40 new models from the Model-AD consortium,
funded through the National Institute on Aging. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH
ANALYSIS, NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+.
Subscribe
